BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33117345)

  • 21. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
    Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
    J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
    Zoroquiain P; Esposito E; Logan P; Aldrees S; Dias AB; Mansure JJ; Santapau D; Garcia C; Saornil MA; Belfort Neto R; Burnier MN
    Mod Pathol; 2018 Aug; 31(8):1201-1210. PubMed ID: 29581543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
    Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
    Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
    Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
    Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
    Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.
    Fujii H; Arakawa A; Utsumi D; Sumiyoshi S; Yamamoto Y; Kitoh A; Ono M; Matsumura Y; Kato M; Konishi K; Shiga T; Sano S; Sakaguchi S; Miyagawa-Hayashino A; Takahashi K; Uezato H; Miyachi Y; Tanioka M
    Int J Cancer; 2014 May; 134(10):2393-402. PubMed ID: 24243586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical Analysis of Foxp3
    Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
    Pathol Oncol Res; 2018 Jul; 24(3):497-505. PubMed ID: 28669079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
    Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
    Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
    Kuklinski LF; Yan S; Li Z; Fisher JL; Cheng C; Noelle RJ; Angeles CV; Turk MJ; Ernstoff MS
    Cancer Immunol Immunother; 2018 Jul; 67(7):1113-1121. PubMed ID: 29737375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
    Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
    Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential prognostic impact of CD8
    Kwak Y; Koh J; Park Y; Hong YJ; Park KU; Kim HH; Park DJ; Ahn SH; Kim WH; Lee HS
    Br J Cancer; 2020 Apr; 122(9):1399-1408. PubMed ID: 32203213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
    Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
    Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.